Controlled, randomized, non-blind trial on the usefulness of pioglitazone treatment in patients with type 2 diabetes mellitus and COVID-19. - ESCORPIO

Fundación Investigación Biomédica Hospital Ramón y Cajal0 个研究点目标入组 76 人开始时间: 2020年7月22日最近更新: 2020年7月27日

适应症

试验速览

暂无简介。

•- Adult patients >18 years old
•- Confirmed diagnosis of COVID-19 or high clinical suspicion according to current criteria.
•- Previous diagnosis of DM2.
•- Patients who provide their informed consent to participate in the study
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 30
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 46

•- Patients under 18 years
•- Known hypersensitivity to the active substance or any of the excipients of the drug.
•- Known history of heart failure or situation at the time of initiation of the cardiac failure study.
•- Liver failure.
•- Dialysis
•- Situation of diabetic ketoacidosis at the time of the start of the study.
•- Diabetes mellitus other than type 2.
•- Active bladder cancer or a history of bladder cancer
•- Non-philated macroscopic hematuria
•- Patients included in another experimental study with another drug.
•- Entry into the Intensive Care Unit.
•- Patients with mechanical ventilation requirement at the time of inclusion.
•- Pregnancy
•- Breastfeeding

发起方

Fundación Investigación Biomédica Hospital Ramón y Cajal